News

Feb 21, 2022

Long-Term clinical outcome study of CounterCOVID patients published

“Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during a 90-day follow-up”

Aug 06, 2021

Further investment and three new appointments announced

Exvastat Ltd (“Exvastat”) receives further investment from Cambridge Innovation Capital and announce expansion of the team with three key new appointments

Jul 12, 2021

First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS

The Impentri IMI2 consortium are pleased to announce the first patients have entered their clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri™) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19

Jun 21, 2021

CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19

Results published on Friday 18th June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 patients. The results of the world-first trial, led by VUmc, Amsterdam, could signify another option in the management of COVID-19 to protect lives

May 18, 2021

Exvastat commence work on EU grant awarded to initiate Phase II trial of IV imatinib for the treatment of COVID-19 pneumonia

18^th May 2021: Cambridge, UK, Exvastat Limited, is pleased to announce it has commenced work on a prestigious European Innovation Council (EIC) accelerator grant, to support development of its innovative treatment, Impentri™ (intravenous imatinib) for the treatment of Acute Respiratory Distress Syndrome (ARDS) related to COVID-19.

Apr 26, 2021

Appointment of Dr Julian Gilbert as Non-Executive Director